Primary Biliary Cholangitis: Clinical Trials

5 trials for Primary Biliary Cholangitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 terminated. 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 25Terminated 5

Follow Primary Biliary Cholangitis: new trials by email Literature Review of Primary Biliary Cholangitis trials Research Report on Primary Biliary Cholangitis

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC
Obeticholic acid, Bezafibrate 200 MG, OCA Placebo - Primary Biliary Cholangitis
Phase 2TerminatedIntercept Pharmaceuticals752019-10-022026-07-16
A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA
Baricitinib, Placebo - Primary Biliary Cholangitis
Phase 2TerminatedEli Lilly and Company22019-03-282020-10-14
Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis
APD334 - Primary Biliary Cholangitis
Phase 2TerminatedArena Pharmaceuticals22017-12-292022-03-24
Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid
E6011, Placebo - Primary Biliary Cholangitis
Phase 2TerminatedEA Pharma Co., Ltd.292017-05-292019-01-04
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis
Cilofexor, Placebo to match cilofexor - Primary Biliary Cholangitis
Phase 2TerminatedGilead Sciences712016-12-012020-09-22

Narrower conditions

Liver Cirrhosis, Biliary (5)  ·  Fibrosis (1)

Broader conditions

Bile Duct Diseases (5)  ·  Biliary Tract Diseases (5)  ·  Cholestasis (5)  ·  Cholestasis, Intrahepatic (5)  ·  Digestive System Diseases (5)  ·  Liver Cirrhosis (5)  ·  Liver Diseases (5)  ·  Pathologic Processes (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Fibrosis (4)

Interventions

Bezafibrate (1)  ·  baricitinib (1)  ·  cilofexor (1)  ·  etrasimod (1)  ·  obeticholic acid (1)  ·  quetmolimab (1)

Sponsors

Arena Pharmaceuticals (1)  ·  EA Pharma Co., Ltd. (1)  ·  Eli Lilly and Company (1)  ·  Gilead Sciences (1)  ·  Intercept Pharmaceuticals (1)

Countries

United States (3)  ·  Australia (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  Belgium (1)  ·  Canada (1)  ·  Croatia (1)  ·  Czechia (1)  ·  Estonia (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Hungary (1)  ·  Israel (1)  ·  Japan (1)

Top investigators

Arena CT.gov Administrator (1)  ·  Lynda Szczech (1)

NIH funding

2016 (1)